Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1989 3
1991 2
1992 1
1993 1
1994 3
1996 1
1997 2
2001 2
2002 1
2006 2
2007 1
2008 5
2009 3
2010 1
2011 1
2012 4
2013 3
2014 2
2016 2
2017 3
2018 1
2019 1
2020 1
2021 1
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Nutritional supplements and doping.
Pipe A, Ayotte C. Pipe A, et al. Among authors: ayotte c. Clin J Sport Med. 2002 Jul;12(4):245-9. doi: 10.1097/00042752-200207000-00008. Clin J Sport Med. 2002. PMID: 12131059 Review.
Sport nutritional supplements: quality and doping controls.
Ayotte C, Lévesque JF, Clé roux M, Lajeunesse A, Goudreault D, Fakirian A. Ayotte C, et al. Can J Appl Physiol. 2001;26 Suppl:S120-9. doi: 10.1139/h2001-047. Can J Appl Physiol. 2001. PMID: 11897888 Review.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
Standardization of reticulocyte counts in the athlete biological passport.
Naud JF, Giraud S, Robinson N, Desharnais P, Ericsson M, Saugy M, Kuuranne T, Ayotte C, Boghosian T, Aikin R, Sottas PE. Naud JF, et al. Among authors: ayotte c. Int J Lab Hematol. 2019 Jun;41(3):387-391. doi: 10.1111/ijlh.12988. Epub 2019 Feb 19. Int J Lab Hematol. 2019. PMID: 30779426
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, Filippi M; ALLEGRO Study Group. Comi G, et al. N Engl J Med. 2012 Mar 15;366(11):1000-9. doi: 10.1056/NEJMoa1104318. N Engl J Med. 2012. PMID: 22417253 Free article. Clinical Trial.
41 results